Eli Lilly (NYSE:LLY) reported strong Q4 2024 results on Thursday, surpassing Wall Street estimates, driven by a more than twofold increase in sales of its weight loss and diabetes drugs Mounjaro and Zepbound.
The Indiana-based drugmaker had preannounced its Q4 figures in January and set its full-year revenue forecast at $58 billion to $61 billion, below analyst expectations. Despite this, shares have rebounded with the company reiterating its revenue outlook and providing adjusted earnings guidance of $22.50 to $24.00 per share for 2025 in line with consensus.
Sales of GLP1 therapy tirzepatide marketed as Mounjaro for diabetes and Zepbound for weight loss reached $5.4 billion reflecting 128% year-over-year growth. Nonincretin revenue climbed 20% year-over-year fueled by diabetes drug Jardiance ($1.2 billion with 50% growth) and breast cancer therapy Verzenio ($1.6 billion with 36% growth).
However Type 2 diabetes medication Trulicity saw sales decline 25% year-over-year to $1.3 billion due to pricing pressures and rising competition. Overall LLY's total revenue surged 45% year-over-year in Q4 boosting full year revenue by 32% to $45 billion. The company's gross margin improved by 1.3 percentage points to 82.2% while net income more than doubled to $4.4 billion.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。